Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Weight-loss drug makers are directly targeting employers in a campaign to expand health insurance coverage of their popular, but pricey, medications.
Makers of Weight-Loss Drugs Want Your Employer to Pay for Them
On a spring day this year, the New Jersey State Policemen’s Benevolent Association received three unusual visitors: pharmaceutical representatives from Eli Lilly.Lilly’s reps presented a slide deck that laid out data on the effectiveness of Lilly’s weight-loss drug Zepbound.
The FDA’s risky action on compounding weight loss drugs
The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes former FDA Commissioner @ScottGottliebMD.
Weight-loss drug coverage rises among largest US employers, Mercer survey finds
Mercer also said 64% of U.S. employers with over 20,000 employees covered weight-loss drugs in 2024, compared with 56% last year. That includes the highly effective newer GLP-1 drugs Wegovy from Novo Nordisk and Eli Lilly's Zepbound that have been shown in trials to reduce weight by 15% to 20%,
Rising Coverage for Weight-Loss Drugs Among U.S. Employers in 2024
In 2024, the percentage of U.S. employers covering weight-loss drugs has increased, with notable rises among larger employers. The trend, partly driven by new GLP-1 drugs, is influencing healthcare costs and accessibility.
‘This Weight Loss Drug Helped My Mental Health Way More Than Any Other Medication’
The weight loss injection tirzepatide helped Melanie Ressa lose weight and overcome food noise, emotional eating, and mental health challenges. Her story, here.
Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.
Government Health Plans Dominate Weight-Loss Drug Coverage
Government health plans in the U.S. provide significant coverage for new weight-loss drugs, overshadowing private insurers. Medicaid is the largest provider, covering 31.6 million people for drugs like Wegovy and Zepbound.
What are your questions about weight loss drugs?
Weight loss and diabetes drugs Ozempic, Wegovy, Mounjaro and Zepbound are seen as game-changers for obesity and weight management but for many people, there are still questions around side effects, accessibility and results.
Employers Get Pressure to Pay for Drugs Like Wegovy
Eli Lilly and Novo Nordisk representatives get facetime with companies in hopes they will cover their weight-loss drugs.
Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says
Investors are fearful RFK Jr.'s critical stance on weight loss drugs could impact pricing or Medicare coverage, but BMO says ...
Lost and found: Life after Ozempic and other weight-loss drugs was just the start for these four people
Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...
KSL2d
Are Ozempic weight loss shots worth side effects? Do better options exist?
Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy, Ozempic, and Rybelsus and similar drugs like Moujaro and Zepbound. And just like all the other ...
Doctors warn of potential dangers from weight loss injections
If you’ve noticed ads for weight loss injections flood your social media feeds, you’re not alone. The soaring popularity of ...